EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

Robert I Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y Lee

Cancer Treatment Reviews · 2023

DOI: 10.1016/j.ctrv.2023.102585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2023. Verfasst von Robert I Haddad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Robert_Haddad@dfc…. Hauptthemen laut MEDLINE: Cisplatin, Head and Neck Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckStandard of CareNeoplasm Recurrence, LocalChemoradiotherapy

Stichwörter der Autor:innen

AdjuvantChemoradiotherapyCisplatin ineligibleLocally advanced squamous cell carcinoma of the head and neckResectedStandard of care

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Robert_Haddad@dfci.harvard.edu.
  • The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Kevin.Harrington@icr.ac.uk.
  • National Cancer Center Hospital East, Kashiwa, Chiba Prefecture, Japan. Electronic address: matahara@east.ncc.go.jp.
  • Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Switzerland. Electronic address: szturz@gmail.com.
  • Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France. Electronic address: christophe.letourneau@curie.fr.
  • Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: satu.salmio@merckgroup.com.

Zitieren

APA

Haddad, R. I., Harrington, K., Tahara, M., Szturz, P., Le Tourneau, C., Salmio, S., Bajars, M., & Lee, N. Y. (2023). Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102585

Vancouver

Haddad RI, Harrington K, Tahara M, Szturz P, Le Tourneau C, Salmio S, et al. Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?. Cancer Treatment Reviews. 2023. doi:10.1016/j.ctrv.2023.102585

BibTeX
@article{Haddad2023,
  author = {Haddad, Robert I and Harrington, Kevin and Tahara, Makoto and Szturz, Petr and Le Tourneau, Christophe and Salmio, Satu and Bajars, Marcis and Lee, Nancy Y},
  title = {Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?},
  journal = {Cancer Treatment Reviews},
  year = {2023},
  doi = {10.1016/j.ctrv.2023.102585}
}
Kostenlos starten →